Safety of epirubicin adjuvant chemotherapy in a breast cancer patient with chronic renal failure undergoing hemodialytic treatment

Tumori

Volumn 92, Issue 4, 2006, Pages 364-365

  Gori, Stefania ^a,c   Rulli, Antonio ^b   Mosconi, Anna Maria ^a   Sidoni, Angelo ^b   Colozza, Mariantonietta ^a   Crinò, Lucio ^a  

^a Perugia Hospital   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Ospedale Silvestrini   (Italy)

Author keywords

Breast cancer; Epirubicin; Hemodialysis

Indexed keywords

EPIRUBICIN;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CASE REPORT; CHRONIC KIDNEY FAILURE; DRUG SAFETY; DRUG TOLERABILITY; EARLY CANCER; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY TRANSPLANTATION; MASTECTOMY; TREATMENT OUTCOME;

EID: 33749523057     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160609200421     Document Type: Article

References (7)

1. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365: 1687-1717, 2005.
2. Sobin LH, Wittekind C: International Union Against Cancer. TNM classification of malignant tumours, 5th Edition, John Wiley & Sons, New York, 1997.
3. Yoshida H, Goto M, Honda A, Nabeshima T, Kumazawa T, Inagaki J, Yamanaka N, Ota K: Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis. Cancer Chemother Pharmacol, 33: 450-454, 1994.
4. Gundersen S, Kvinnsland S, Klepp O, Kvaloy S, Lunds E, Host H: Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial. Eur J Cancer Oncol, 22: 1431-1434, 1986.
5. Gundersen S, Kvinnsland S, Klepp O, Lunds E, Host H: Weekly adriamycin vs. 4-epidoxorubicin every second week in advanced breast cancer. A randomized trial. The Norvegian Breast Cancer Group. Eur J Cancer, 26: 45-48, 1990.
6. Blomqvist C, Elomaa I, Rissanen P, Hietanen P, Nevasaari K, Helle L: Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration. J Clin Oncol, 11: 467-473, 1993.
7. Colozza M, Bisagni G, Mosconi AM, Gori S, Boni C, Sabbatini R, Frassoldati A, Passalacqua R, Rosa Bian A, Rodinò C, Rondini E, Algeri R, Di Sarra S, De Angelis V, Cocconi G, Tonato M: Epirubicin vs CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study. Eur J Cancer, 38: 2279-2288, 2002.